Signal transduction in prostate cancer progression

Clinical Science

Volumn 108, Issue 4, 2005, Pages 293-308

  Gioeli, Daniel ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Androgen receptor (AR); Growth factor; Mitogen activated protein kinase (MAP kinase); Prostate; Ras; Systems theory

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; GROWTH FACTOR;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE;

DISEASE PROGRESSION; GENES, RAS; GROWTH SUBSTANCES; HUMANS; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS, HORMONE-DEPENDENT; PHOSPHORYLATION; PROSTATIC NEOPLASMS; RAS PROTEINS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION;

EID: 17144364645     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20040329     Document Type: Review

References (179)

1. American Cancer Society (2004) Cancer Facts and Figures
2. Perez, C. A., Flair, W. R., Ihde, D. C. and Labrie, F. (1985) Cancer of the prostate. In Principles and Practice of Oncology (DeVita, V. T., Hellman, S. and Rosenberg, S. A., eds.) pp. 929-964, J. B. Lippincott Company, Philadelphia
3. Gregory, C. W., Johnson, Jr, R. T., Mohler, J. L., French, F. S. and Wilson, E. M. (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61, 2892-2898
4. Chen, C. D., Welsbie, D. S., Tran, C. et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 10, 33-39
5. Reinikainen, P., Palvimo, J. J. and Janne, O. A. (1996) Effects of mitogens on androgen receptor-mediated transactivation. Endocrinology 137, 4351-4357
6. Weber, M. J. and Gioeli, D. (2004) Ras signaling in prostate cancer progression. J. Cell Biochem. 91, 13-25
7. McNeal, J. E. and Bostwick, D. G. (1986) Intraductal dysplasia: a premalignant lesion of the prostate. Hum. Pathol. 17, 64-71
8. Verhagen, A. P., Ramaekers, F. C., Aalders, T. W., Schaafsma, H. E., Debruyne, F. M. and Schalken, J. A. (1992) Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res. 52, 6182-6187
9. De Marzo, A. M., Nelson, W. G., Meeker, A. K. and Coffey, D. S. (1998) Stem cell features of benign and malignant prostate epithelial cells. J. Urol. 160, 2381-2392
10. Miller, G. J. and Cygan, J. M. (1994) Morphology of prostate cancer: the effects of multifocality on histological grade, tumor volume and capsule penetration. J. Urol. 152, 1709-1713
11. Ruijter, E. T., van de Kaa, C. A., Schalken, J. A., Debruyne, F. M. and Ruiter, D. J. (1996) Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications. J. Pathol. 180, 295-299
12. Ruijter, E. T., Miller, G. J., van de Kaa, C. A. et al. (1999) Molecular analysis of multifocal prostate cancer lesions. J. Pathol. 188, 271-277
13. Sakr, W. A., Macoska, J. A., Benson, P. et al. (1994) Allelic loss in locally metastatic, multisampled prostate cancer. Cancer Res. 54, 3273-3277
14. Konishi, N., Hiasa, Y, Matsuda, H. et al. (1995) Intratumor cellular heterogeneity and alterations in ras oncogene and p53 tumor suppressor gene in human prostate carcinoma. Am. J. Pathol. 147, 1112-1122
15. Senge, P. M. (1990) The Fifth Discipline: the Art and Practice of the Learning Organization. Doubleday, New York
16. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70
17. Culig, Z., Hobisch, A., Cronauer, M. V. et al. (1996) Regulation of prostatic growth and function by peptide growth factors. Prostate 28, 392-405
18. Litvinov, I. V., De Marzo, A. M. and Isaacs, J. T. (2003) Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J. Clin. Endocrinol. Metab. 88, 2972-2982
19. Culig, Z., Hobisch, A., Bartsch, G. and Klocker, H. (2000) Androgen receptor: an update of mechanisms of action in prostate cancer. Urol. Res. 28, 211-219
20. Culig, Z., Klocker, H., Bartsch, G. and Hobisch, A. (2002) Androgen receptors in prostate cancer. Endocr. Relat. Cancer. 9, 155-170
21. Scher, H. I., Sarkis, A., Reuter, V. et al. (1995) Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor a in the progression of prostatic neoplasms. Clin. Cancer Res. 1, 545-550
22. Culig, Z., Hobisch, A., Cronauer, M. V. et al. (1994) Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res. 54, 5474-5478
23. Scher, H. I., Sarkis, A., Reuter, V. et al. (1995) Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor a in the progression of prostatic neoplasms. Clin. Cancer Res. 1, 545-550
24. Thalmann, G. N., Anezinis, P. E., Chang, S. M. et al. (1994) Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 54, 2577-2581
25. Nakamoto, T., Chang, C. S., Li, A. K. and Chodak, G. W. (1992) Basic fibroblast growth factor in human prostate cancer cells. Cancer Res. 52, 571-577
26. Gleave, M. E., Hsieh, J. T., von Eschenbach, A. C. and Chung, L. W. (1992) Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J. Urol. 147, 1151-1159
27. Pietrzkowski, Z., Mulholland, G., Cornelia, L., Jameson, B. A., Wernicke, D. and Baserga, R. (1993) Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 53, 1102-1106
28. Kitsberg, D. I. and Leder, P. (1996) Keratinocyte growth factor induces mammary and prostatic hyperplasia and mammary adenocarcinoma in transgenic mice. Oncogene 13, 2507-2515
29. Culig, Z., Bartsch, G. and Hobisch, A. (2002) Interleukin-6 regulates androgen receptor activity and prostate cancer cell growth. Mol. Cell. Endocrinol. 197, 231-238
30. Steiner, H., Godoy-Tundidor, S., Rogatsch, H. et al. (2003) Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am. J. Path. 162, 655-663
31. Nazareth, L. V. and Weigel, N. L. (1996) Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem. 271, 19900-19907
32. Weigel, N. L. and Zhang, Y. (1998) Ligand-independent activation of steroid hormone receptors. J. Mol. Med. 76, 469-479
33. Weigel, N. L. (1996) Steroid hormone receptors and their regulation by phosphorylation. Biochem. J. 319, 657-667
34. Ikonen, T., Palvimo, J. J., Kallio, P. J., Reinikainen, P. and Janne, O. A. (1994) Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation. Endocrinology 135, 1359-1366
35. Nazareth, L. V. and Weigel, N. L. (1996) Activation of the human androgen receptor through a protein kinase A signaling pathway. J. Biol. Chem. 271, 19900-19907
36. Sadar, M. D. (1999) Androgen-independent induction of prostate-specific antigen gene expression via cross-talk between the androgen receptor and protein kinase A signal transduction pathways. J. Biol. Chem. 274, 7777-7783
37. Craft, N., Shostak, Y., Carey, M. and Sawyers, C. L. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5, 280-285
38. Yeh, S., Lin, H. K., Kang, H. Y., Thin, T. H., Lin, M. F. and Chang, C. (1999) From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A. 96, 5458-5463
39. Mellinghoff, I. K., Tran, C. and Sawyers, C. L. (2002) Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res. 62, 5254-5259
40. Agus, D. B., Akita, R. W., Fox, W. D. et al. (2002) Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell. 2, 127-137
41. Savinainen, K. J., Saramaki, O. R., Linja, M. J. et al. (2002) Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am. J. Pathol. 160, 339-345
42. Calvo, B. F., Levine, A. M., Marcos, M. et al. (2003) Human epidermal receptor-2 expression in prostate cancer. Clin. Cancer Res. 9, 1087-1097
43. Osman, I., Scher, H. I., Drobnjak, M. et al. (2001) HER-2/neu (p185neu) protein expression in the natural or treated history of prostate cancer. Clin. Cancer Res. 7, 2643-2647
44. Signoretti, S., Montironi, R., Manola, J. et al. (2000) Her-2-neu expression and progression toward androgen independence in human prostate cancer. J. Natl. Cancer Inst. 92, 1918-1925
45. Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J. and Sawyers, C. L. (2004) HER2/new kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell. 6, 1-11
46. Carter, B. S., Epstein, J. I. and Isaacs, W B. (1990) ras gene mutations in human prostate cancer. Cancer Res. 50, 6830-6832
47. Bar-Sagi, D. (2001) A Ras by any other name. Mol. Cell Biol. 21, 1441-1443
48. Berthiaume, L. G. (2002) Insider information: how palmitoylation of Ras makes it a signaling double agent. Science STKE 2002, PE41
49. Ehrhardt, A., Ehrhardt, G. R., Guo, X. and Schrader, J. W. (2002) Ras and relatives-job sharing and networking keep an old family together. Exp. Hematol. 30, 1089-1106
50. Bos, J. L. (1989) ras oncogenes in human cancer: a review. Cancer Res. 49, 4682-4689
51. Lowy, D. R. and Willumsen, B. M. (1993) Function and regulation of ras. Annu. Rev. Biochem. 62, 851-891
52. Umanoff, H., Edelmann, W., Pellicer, A. and Kucherlapati, R. (1995) The murine N-ras gene is not essential for growth and development. Proc. Natl. Acad. Sci. U.S.A. 92, 1709-1713
53. Koera, K., Nakamura, K., Nakao, K. et al. (1997) K-ras is essential for the development of the mouse embryo. Oncogene. 15, 1151-1159
54. Johnson, L., Greenbaum, D., Cichowski, K. et al. (1997) K-ras is an essential gene in the mouse with partial functional overlap with N-ras. Genes Dev. 11, 2468-2481
55. Esteban, L. M., Vicario-Abejon, C., Fernandez-Salguero, P. et al. (2001) Targeted genomic disruption of H-ras and N-ras, individually or in combination, reveals the dispensability of both loci for mouse growth and development. Mol. Cell. Biol. 21, 1444-1452
56. Prior, I. A., Harding, A., Yan, J., Sluimer, J., Parton, R. G. and Hancock, J. F. (2001) GTP-dependent segregation of H-ras from lipid rafts is required for biological activity. Nat. Cell Biol. 3, 368-375
57. Roy, S., Luetterforst, R., Harding, A. et al. (1999) Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat. Cell Biol. 1, 98-105
58. Mineo, C., James, G. L., Smart, E. J. and Anderson, R. G. (1996) Localization of epidermal growth factor-stimulated Ras/Raf-1 interaction to caveolae membrane. J. Biol. Chem. 271, 11930-11935
59. Furuchi, T. and Anderson, R. G. (1998) Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK). J. Biol. Chem. 273, 21099-21104
60. Shields, J. M., Pruitt, K., McFall, A., Shaub, A. and Der, C. J. (2000) Understanding Ras: 'it ain't over 'til it's over'. Trends Cell Biol. 10, 147-154
61. Gioeli, D., Zecevic, M. and Weber, M. J. (2001) Immunostaining for activated extracellular signal-regulated kinases in cells and tissues. Methods Enzymol. 332, 343-353
62. Gioeli, D., Mandell, J. W., Petroni, G. R., Frierson, Jr, H. F. and Weber, M. J. (1999) Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 59, 279-284
63. Voeller, H. J., Wilding, G. and Gelmann, E. P. (1991) v-rasH expression confers hormone-independent in vitro growth to LNCaP prostate carcinoma cells. Mol. Endocrinol. 5, 209-216
64. Bakin, R. E., Gioeli, D., Sikes, R. A., Bissonette, E. A. and Weber, M. J. (2003) Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res. 63, 1981-1989
65. Thalmann, G. N., Sikes, R. A., Wu, T. T. et al. (2000) LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate 44, 91-103
66. Bakin, R. E., Gioeli, D., Bissonette, E. A. and Weber, M. J. (2003) Attenuation of Ras signaling restores androgen sensitivity to hormone-refractory C4-C2 prostate cancer cells. Cancer Res. 63, 1975-1980
67. Repasky, G. A., Chenette, E. J. and Der, C. J. (2004) Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol. 14, 639-647
68. Carson, J. P., Kulik, G. and Weber, M. J. (1999) Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res. 59, 1449-1453
69. Murillo, H., Huang, H., Schmidt, L. J., Smith, D. I. and Tindall, D. J. (2001) Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology. 142, 4795-4805
70. Cairns, P., Okami, K., Halachmi, S. et al. (1997) Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57, 4997-5000
71. McMenamin, M. E., Soung, P., Perera, S., Kaplan, I., Loda, M. and Sellers, W. R. (1999) Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59, 4291-4296
72. Whang, Y. E., Wu, X., Suzuki, H. et al. (1998) Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. U.S.A. 95, 5246-5250
73. Carson, J. P., Kulik, G. and Weber, M. J. (1999) Antiapoptotic signaling in LNCaP prostate cancer cells: a survival signaling pathway independent of phosphatidylinositol 3′-kinase and Akt/protein kinase B. Cancer Res. 59, 1449-1453
74. Vos, M. D., Ellis, C. A., Bell, A., Birrer, M. J. and Clark, G. J. (2000) Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem. 275, 35669-35672
75. Vos, M. D., Ellis, C. A., Elam, C., Ulku, A. S., Taylor, B. J. and Clark, G. J. (2003) RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J. Biol. Chem. 278, 28045-28051
76. Vos, M. D., Martinez, A., Ellis, C. A., Vallecorsa, T. and Clark, G. J. (2003) The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J. Biol. Chem. 278, 21938-21943
77. Tommasi, S., Dammann, R., Jin, S. G., Zhang, X. F., Avruch, J. and Pfeifer, G. P. (2002) RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 21, 2713-2720
78. Dreijerink, K., Braga, E., Kuzmin, I. et al. (2001) The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc. Natl. Acad. Sci. U.S.A. 98, 7504-7509
79. Dammann, R., Li, C., Yoon, J. H., Chin, P. L., Bates, S. and Pfeifer, G. P. (2000) Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat. Genet. 25, 315-319
80. Hesson, L., Dallol, A., Minna, J. D., Maher, E. R. and Latif, F. (2003) NORE1A, a homologue of RASSF1A tumour suppressor gene is inactivated in human cancers. Oncogene 22, 947-954
81. Khokhlatchev, A., Rabizadeh, S., Xavier, R. et al. (2002) Identification of a novel Ras-regulated proapoptotic pathway. Curr. Biol. 12, 253-265
82. Feig, L. A., Urano, T. and Cantor, S. (1996) Evidence for a Ras/Ral signaling cascade. Trends Biochem. Sci. 21, 438-441
83. Innocenti, M., Tenca, P., Frittoli, E. et al. (2002) Mechanisms through which Sos-1 coordinates the activation of Ras and Rac. J. Cell Biol. 156, 125-136
84. Walsh, A. B. and Bar-Sagi, D. (2001) Differential activation of the Rac pathway by Ha-Ras and K-Ras. J. Biol. Chem. 276, 15609-15615
85. Ward, Y., Wang, W., Woodhouse, E., Linnoila, I., Liotta, L. and Kelly, K. (2001) Signal pathways which promote invasion and metastasis: critical and distinct contributions of extracellular signal-regulated kinase and Ral-specific guanine exchange factor pathways. Mol. Cell Biol. 21, 5958-5969
86. Weijzen, S., Rizzo, P., Braid, M. et al. (2002) Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat. Med. 8, 979-986
87. Weston, C. R. and Davis, R. J. (2002) The JNK signal transduction pathway. Curr. Opin. Genet. Dev. 12, 14-21
88. Hamad, N. M., Elconin, J. H., Karnoub, A. E. et al. (2002) Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev. 16, 2045-2057
89. Kitayama, H., Sugimoto, Y., Matsuzaki, T., Ikawa, Y. and Noda, M. (1989) A ras-related gene with transformation suppressor activity. Cell 56, 77-84
90. Stork, P.J. (2003) Does Rap1 deserve a bad Rap? Trends Biochem. Sci. 28, 267-275
91. Stork, P. J. and Schmitt, J. M. (2002) Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol. 12, 258-266
92. Chen, T., Cho, P. W., Stork, P. J. and Weber, M. J. (1999) Elevation of cyclic adenosine 3′,5′-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells. Cancer Res. 59, 213-218
93. Gelmann, E. P. (2002) Molecular biology of the androgen receptor. J. Clin. Oncol. 20, 3001-3015
94. Aarnisalo, P., Palvimo, J. J. and Janne, O. A. (1998) CREB-binding protein in androgen receptor-mediated signaling. Proc. Natl. Acad. Sci. U.S.A. 95, 2122-2127
95. Bubulya, A., Wise, S. C., Shen, X. Q., Burmeister, L. A. and Shemshedini, L. (1996) c-Jun can mediate androgen receptor-induced transactivation. J. Biol. Chem. 271, 24583-24589
96. Bubulya, A., Zhou, X. F., Shen, X. Q., Fisher, C. J. and Shemshedini, L. (2000) c-Jun targets amino terminus of androgen receptor in regulating androgen-responsive transcription. Endocrine 13, 55-62
97. Bubulya, A., Chen, S. Y., Fisher, C. J., Zheng, Z., Shen, X. Q. and Shemshedini, L. (2001) c-Jun potentiates the functional interaction between the amino and carboxyl termini of the androgen receptor. J. Biol. Chem. 276, 44704-44711
98. Comuzzi, B., Lambrinidis, L., Rogatsch, H. et al. (2003) The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and antiandrogen-induced androgen receptor function. Am. J. Path. 162, 233-241
99. Doesburg, P., Kuil, C. W., Berrevoets, C. A. et al. (1997) Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36, 1052-1064
100. Fronsdal, K., Engedal, N., Slagsvold, T. and Saatcioglu, F. (1998) CREB binding protein is a coactivator for the androgen receptor and mediates cross-talk with AP-1. J. Biol. Chem. 273, 31853-31859
101. Gelmann, E. P. (2002) Molecular biology of the androgen receptor. J. Clin. Oncol. 20, 3001-3015
102. Kotaja, N., Karvonen, U., Janne, O. A. and Palvimo, J. J. (2002) The nuclear receptor interaction domain of GRIP1 is modulated by covalent attachment of SUMO-1. J. Biol. Chem. 11, 11
103. Kotaja, N., Karvonen, U., Janne, O. A. and Palvimo, J. J. (2002) PIAS proteins modulate transcription factors by functioning as SUMO-1 ligases. Mol. Cell Biol. 22, 5222-5234
104. Langley, E., Zhou, Z. X. and Wilson, E. M. (1995) Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J. Biol. Chem. 270, 29983-29990
105. McKenna, N. J. and O'Malley, B. W (2002) Minireview: nuclear receptor coactivators-an update. Endocrinology 143, 2461-2465
106. McKenna, N. J. and O'Malley, B. W. (2002) Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108, 465-474
107. Nessler-Menardi, C., Jotova, I., Culig, Z. et al. (2000) Expression of androgen receptor coregulatory proteins in prostate cancer and stromal-cell culture models. Prostate 45, 124-131
108. Reutens, A. T., Fu, M., Wang, C. et al. (2001) Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol. Endocrinol. 15, 797-811
109. Tillman, K., Oberfield, J. L., Shen, X. Q., Bubulya, A. and Shemshedini, L. (1998) c-Fos dimerization with c-Jun represses c-Jun enhancement of androgen receptor transactivation. Endocrine 9, 193-200
110. Wise, S. C., Burmeister, L. A., Zhou, X. F. et al. (1998) Identification of domains of c-Jun mediating androgen receptor transactivation. Oncogene 16, 2001-2009
111. Heinlein, C. A. and Chang, C. (2002) Androgen receptor (AR) coregulators: an overview. Endocrin. Rev. 23, 175-200
112. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H. and Hittmair, A. (1995) Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res. 55, 3068-3072
113. Linja, M. J., Savinainen, K. J., Saramaki, O. R., Tammela, T. L., Vessella, R. L. and Visakorpi, T. (2001) Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer. Cancer Res. 61, 3550-3555
114. Brown, R. S., Edwards, J., Dogan, A. et al. (2002) Amplification of the androgen receptor gene in bone metastases from hormone-refractory prostate cancer. J. Pathol. 198, 237-244
115. Bentel, J. M. and Tilley, W. D. (1996) Androgen receptors in prostate cancer. J. Endocrinol. 151, 1-11
116. Culig, Z., Klocker, H., Bartsch, G. and Hobisch, A. (2001) Androgen receptor mutations in carcinoma of the prostate: significance for endocrine therapy. Am. J. Pharmacogenomics 1, 241-249
117. Isaacs, W., De Marzo, A. and Nelson, W. G. (2002) Focus on prostate cancer. Cancer Cell. 2, 113-116
118. Gregory, C. W., He, B., Johnson, R. T. et al. (2001) A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 61, 4315-4319
119. Yeh, S., Kang, H. Y., Miyamoto, H. et al. (1999) Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine 11, 195-202
120. Zegarra-Moro, O. L., Schmidt, L. J., Huang, H. and Tindall, D. J. (2002) Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Res. 62, 1008-1013
121. Eder, I. E., Hoffmann, J., Rogatsch, H. et al. (2002) Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Ther. 9, 117-125
122. Eder, I. E., Culig, Z., Ramoner, R. et al. (2000) Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther. 7, 997-1007
123. Gregory, C. W., Johnson, Jr, R. T., Mohler, J. L., French, F. S. and Wilson, E. M. (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res. 61, 2892-2898
124. Yeh, S., Chang, H. C., Miyamoto, H. et al. (1999) Differential induction of the androgen receptor transcriptional activity by selective androgen receptor coactivators. Keio J. Med. 48, 87-92
125. Rowan, B. G., Garrison, N., Weigel, N. L. and O'Malley, B. W (2000) 8-Bromo-cyclic AMP induces phosphorylation of two sites in SRC-1 that facilitate ligand-independent activation of the chicken progesterone receptor and are critical for functional cooperation between SRC-1 and CREB binding protein. Mol. Cell Biol. 20, 8720-8730
126. Zhou, Z. X., Kemppainen, J. A. and Wilson, E. M. (1995) Identification of three proline-directed phosphorylation sites in the human androgen receptor. Mol. Endocrinol. 9, 605-615
127. Jenster, G., de Ruiter, P. E., van der Korput, H. A., Kuiper, G. G., Trapman, J. and Brinkmann, A. O. (1994) Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. Biochemistry 33, 14064-14072
128. Lin, H. K., Yeh, S., Kang, H. Y. and Chang, C. (2001) Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor. Proc. Natl. Acad. Sci. U.S.A. 98, 7200-7205
129. Wen, Y., Hu, M. C., Makino, K. et al. (2000) HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res. 60, 6841-6845
130. Lubahn, D. B., Joseph, D. R., Sullivan, P. M., Willard, H. F., French, F. S. and Wilson, E. M. (1988) Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240, 327-330
131. Lubahn, D. B., Joseph, D. R., Sar, M. et al. (1988) The human androgen receptor: complementary deoxyribonucleic acid cloning, sequence analysis and gene expression in prostate. Mol. Endocrinol. 2, 1265-1275
132. Zhu, Z., Bulgakov, O. V., Scott, S. S. and Dalton, J. T. (2001) Recombinant expression and purification of human androgen receptor in a baculovirus system. Biochem. Biophys. Res. Commun. 284, 828-835
133. Gioeli, D., Ficarro, S. B., Kwiek, J. J. et al. (2002) Androgen receptor phosphorylation. Regulation and identification of the phosphorylation sites. J. Biol. Chem. 277, 29304-29314
134. McKenna, N. J. and O'Malley, B. W. (2002) Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 108, 465-474
135. Fu, M., Wang, C., Wang, J. et al. (2002) Androgen receptor acetylation governs trans activation and MEKK1-induced apoptosis without affecting in vitro sumoylation and trans-repression function. Moll. Cell Biol. 22, 3373-3388
136. Gaughan, L., Logan, I. R., Cook, S., Neal, D. E. and Robson, C. N. (2002) Tip60 and histone deacetylase 1 regulate androgen receptor activity through changes to the acetylation status of the receptor. J. Biol. Chem. 277, 25904-25913
137. Geiman, T. M. and Robertson, K. D. (2002) Chromatin remodeling, histone modifications, and DNA methylation: how does it all fit together? J. Cell Biochem. 87, 117-125
138. Berger, S. L. (2002) Histone modifications in transcriptional regulation. Curr. Opin. Genet. Dev. 12, 142-148
139. Featherstone, M. (2002) Coactivators in transcription initiation: here are your orders. Curr. Opin. Genet. Dev. 12, 149-155
140. He, Z., Ma, W. Y., Liu, G., Zhang, Y., Bode, A. M. and Dong, Z. (2003) Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1. J. Biol. Chem. 278, 10588-10593
141. Strelkov, I. S. and Davie, J. R. (2002) Ser-10 phosphorylation of histone H3 and immediate early gene expression in oncogene-transformed mouse fibroblasts. Cancer Res. 62, 75-78
142. Cheung, P., Allis, C. D. and Sassone-Corsi, P. (2000) Signaling to chromatin through histone modifications. Cell 103, 263-271
143. Sassone-Corsi, P., Mizzen, C. A., Cheung, P. et al. (1999) Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Science 285, 886-891
144. Chrivia, J. C., Kwok, R. P., Lamb, N., Hagiwara, M., Montminy, M. R. and Goodman, R. H. (1993) Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature (London) 365, 855-859
145. Goodman, R. H. and Smolik, S. (2000) CBP/p300 in cell growth, transformation, and development. Genes Dev. 14, 1553-1577
146. Chadee, D. N., Hendzel, M. J., Tylipski, C. P. et al. (1999) Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J. Biol. Chem. 274, 24914-24920
147. Font, d. M. and Brown, M. (2000) AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor. Mol. Cell Biol. 20, 5041-5047
148. Gnanapragasam, V. J., Leung, H. Y., Pulimood, A. S., Neal, D. E. and Robson, C. N. (2001) Expression of RAC3, a steroid hormone receptor co-activator in prostate cancer. Br. J. Cancer 85, 1928-1936
149. Rowan, B. G., Weigel, N. L. and O'Malley, B. W. (2000) Phosphorylation of steroid receptor coactivator-1. Identification of the phosphorylation sites and phosphorylation through the mitogen-activated protein kinase pathway. J. Biol. Chem. 275, 4475-4483
150. Wu, R. C., Qin, J., Hashimoto, Y. et al. (2002) Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) Coactivator activity by IκB kinase. Mol. Cell Biol. 22, 3549-3561
151. Gregory, C. W., Fei, X., Ponguta, L. A. et al. (2004) Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. J. Biol. Chem. 279, 7119-7130
152. Xu, J., Qiu, Y., DeMayo, F. J., Tsai, S. Y., Tsai, M. J. and O'Malley, B. W. (1998) Partial hormone resistance in mice with disruption of the steroid receptor coactivator-1 (SRC-1) gene. Science 279, 1922-1925
153. Debes, J. D., Schmidt, L. J., Huang, H. and Tindall, D. J. (2002) P300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res. 62, 5632-5636
154. Debes, J. and Tindall, D. (2002) The role of androgens and the androgen receptor in prostate cancer. Cancer Lett. 187, 1
155. Huang, H. and Tindall, D. J. (2002) The role of the androgen receptor in prostate cancer. Crit. Rev. Eukaryot. Gene Expr. 12, 193-207
156. Yeung, F., Li, X., Ellett, J., Trapman, J., Kao, C. and Chung, L. W. (2000) Regions of prostate-specific antigen (PSA) promoter confer androgen-independent expression of PSA in prostate cancer cells. J. Biol. Chem. 275, 40846-40855
157. Poukka, H., Karvonen, U., Janne, O. A. and Palvimo, J. J. (2000) Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1). Proc. Natl. Acad. Sci. U.S.A. 97, 14145-14150
158. Stallcup, M. R. (2001) Role of protein methylation in chromatin remodeling and transcriptional regulation. Oncogene 20, 3014-3020
159. Dai, J., Shen, R., Sumitomo, M. et al. (2002) Synergistic activation of the androgen receptor by bombesin and low-dose androgen. Clin. Cancer Res. 8, 2399-2405
160. Darne, C., Veyssiere, G. and Jean, C. (1998) Phorbol ester causes ligand-independent activation of the androgen receptor. Eur. J. Biochem. 256, 541-549
161. de Ruiter, P. E., Teuwen, R., Trapman, J., Dijkema, R. and Brinkmann, A. O. (1995) Synergism between androgens and protein kinase-C on androgen-regulated gene expression. Mol. Cell. Endocrinol. 110, R1-R6
162. Di Lorenzo, G., Tortora, G., D'Armiento, F. P. et al. (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res. 8, 3438-3444
163. Reinikainen, P., Palvimo, J. J. and Janne, O. A. (1996) Effects of mitogens on androgen receptor-mediated transactivation. Endocrinology 137, 4351-4357
164. Abreu-Martin, M. T., Chari, A., Palladino, A. A., Craft, N. A. and Sawyers, C. L. (1999) Mitogen-activated protein kinase kinase kinase 1 activates androgen receptor-dependent transcription and apoptosis in prostate cancer. Mol. Cell Biol. 19, 5143-5154
165. Chen, C. D. and Sawyers, C. L. (2002) NF-κB activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol. Cell Biol. 22, 2862-2870
166. Craft, N. and Sawyers, C. L. (1998) Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Met. Rev. 17, 421-427
167. Craft, N., Shostak, Y., Carey, M. and Sawyers, C. L. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med. 5, 280-285
168. Mellinghoff, I. K., Tran, C. and Sawyers, C. L. (2002) Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts. Cancer Res. 62, 5254-5259
169. Nickerson, T., Chang, F., Lorimer, D., Smeekens, S. P., Sawyers, C. L. and Pollak, M. (2001) In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res. 61, 6276-6280
170. Gregory, C. W., Hamil, K. G., Kim, D. et al. (1998) Androgen receptor expression in androgen-independent prostate cancer is associated with increased expression of androgen-regulated genes. Cancer Res. 58, 5718-5724
171. Grossmann, M. E., Huang, H. and Tindall, D. J. (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J. Nat. Cancer Inst. 93, 1687-1697
172. Dancey, J. E. and Freidlin, B. (2003) Targeting epidermal growth factor receptor: are we missing the mark? Lancet 362, 62-64
173. Agus, D. B., Akita, R. W., Fox, W. D. et al. (2000) A potential role for activated HER-2 in prostate cancer. Semin. Oncol. 27, 76-83
174. Wright, J. D., Reuter, C. W. and Weber, M. J. (1995) An incomplete program of cellular tyrosine phosphorylations induced by kinase-defective epidermal growth factor receptors. J. Biol. Chem. 270, 12085-12093
175. Coker, K. J., Staros, J. V. and Guyer, C. A. (1994) A kinase-negative epidermal growth factor receptor that retains the capacity to stimulate DNA synthesis. Proc. Natl. Acad. Sci. U.S.A. 91, 6967-6971
176. Kitano, H. (2004) Cancer as a robust system: implications for anticancer therapy. Nat. Rev. Cancer 4, 227-235
177. Gorre, M. E., Mohammed, M., Ellwood, K. et al. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880
178. Shah, N. P., Tran, C., Lee, F. Y., Chen, P., Norris, D. and Sawyers, C. L. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401
179. Allen, L. F., Sebolt-Leopold, J. and Meyer, M. B. (2003) CI-1040 (PD 184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 30, 105-116